The EV-based Liquid Biopsy Market Size is valued at 74.61 Million in 2022 and is predicted to reach 349.19 Million by the year 2031 at an 18.9% CAGR during the forecast period for 2023-2031.
EVs (Extracellular Vesicles) can be categorized based on their cellular origin or size. EVs derived from the intracellular endosomal system are called "exosomes", and vesicles from the plasma membrane are known as "ectosomes" or "microvesicles". Extracellular vesicles are present in all human biofluids and contain DNA, RNA, and proteins originating from their parent cells.
Several clinical research studies have highlighted extracellular vesicles (EVs) as a promising source of novel tumor biomarkers. Tumor EVs in body fluids such as blood have unique properties of cells of origin, making them ideal biomarker candidates for detecting, evaluating, and monitoring tumor growth in liquid biopsies. However, using EVs as cancer biomarkers in routine diagnosis is still hampered by a lack of standardization, data from large patient cohorts, and methodological challenges. Once these issues have been resolved, EVs alone or in combination with other body fluids have the potential to be useful tools in liquid biopsies.
Rising cancer awareness is driving the growth of the EV-based liquid biopsy industry, as liquid biopsy technology can detect cancer at an early stage, monitor tumors, and evaluate diagnosis. In addition, advanced technology development has increased the demand for non-invasive diagnosis and treatment, which is expected to boost the demand for EV-based liquid biopsy in the upcoming years.
Competitive Landscape:
Some of the Key Players in the EV-based Liquid Biopsy Market:
- Abcam plc
- AMS Biotechnology Limited (AMSBIO)
- Bio-Techne Corporation
- Horiba Ltd.
- Qiagen N.V.
- Thermo Fisher Scientific, Inc.
- Lonza Group AG
- Malvern Panalytical Ltd
- Revvity, Inc. (PerkinElmer, Inc.)
- Takara Bio Inc.
- Emerging Companies
- Mursla Bio
- Nanostics Inc.
- Mercy BioAnalytics, Inc.
- Clara Diagnostics, Inc. (Clara Biotech)
- Other Prominent Players
Market Segmentation:
The EV-based Liquid Biopsy Market is segmented into offering, workflow, technology, sample type, and end user. By offering, the market is categorized into kits & assays, instruments, and services. The workflow segment comprises sample preparation, sequencing, and data analysis. Based on technology, the market is bifurcated into isolation technologies and detection technologies. The sample type segment is classified into blood (plasma/serum), urine, saliva, other biofluids (CF- cerebrospinal fluid), cell culture. The end user segment consists of academic & research institutions, clinical laboratories, and pharmaceutical & biotechnology companies.
By Offering, The Kits And Assays Segment Held The Maximum Market Share In 2022
The Kits and Assays segment held the largest EV-based Liquid Biopsy Market share in 2022. The growth can be due to the rising demand for kits. The liquid biopsy market relies on the distance collection of samples by transporting the diagnostics kits to the patient.
By Workflow, The Sequencing Segment Held The Largest Market Share
In 2022, the Sequencing segment held the largest share of the EV-based Liquid Biopsy Market. The increasing adoption of sequencing, advancements & high efficiency of the Next Generation Sequencing technology to detect the lower frequency variants of cancer are responsible for market expansion.
Detection Technologies Witnessed Growth At A Rapid Rate In The Market
Factors such as the increasing need for early disease detection and diagnosis, rising public healthcare awareness, and the demand for quick and real-time diagnostic results are expected to boost the demand for detection technologies and, ultimately, for the EV-based Liquid Biopsy Market.
In Terms Of End Users, The Clinical Laboratories Segment Dominates The Market
In 2022, the clinical laboratories segment led the EV-based Liquid Biopsy Market and is expected to continue its trend over the projected period, followed by the Pharmaceutical and Biotechnology Companies segment. This is due to the high prevalence of cancer and rising clinical R&D efforts for improving liquid biopsy techniques.
Regionally, North America Captured The Highest Market Share In 2022
The largest portion of the EV-based Liquid Biopsy Market was held by North America in 2022. The market in this region is being driven by the increasing demand for non-invasive treatments, surging awareness about the applications of liquid biopsies, and rising research efforts to improve early cancer detection. At the same time, the Asia Pacific regional market is expected to witness the fastest growth during the forecast period. Factors such as the escalating cancer cases, increasing adoption of advanced diagnosis techniques, and the increasing government investments in oncology research and treatment are responsible for the blooming of the EV-based Liquid Biopsy Market in Asia Pacific.
EV-based Liquid Biopsy Market Report Scope:
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 74.61 Million |
|
Revenue Forecast In 2031 |
USD 349.19 Million |
|
Growth Rate CAGR |
CAGR of 18.9% from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Offering, By Workflow, By Technology, By Sample Type, By End User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Abcam plc, AMS Biotechnology Limited (AMSBIO), Bio-Techne Corporation, Horiba Ltd., Qiagen N.V., Thermo Fisher Scientific, Inc., Lonza Group AG, Malvern Panalytical Ltd, Revvity, Inc. (PerkinElmer, Inc.), Takara Bio Inc., Emerging Companies, Mursla Bio, Nanostics Inc., Mercy BioAnalytics, Inc., Clara Diagnostics, Inc. (Clara Biotech), and others. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
